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A bs tr ac t
Background
In patients with type 2 diabetes, the effects of intensive glucose control on vascular 
outcomes remain uncertain.
Methods
We randomly assigned 11,140 patients with type 2 diabetes to undergo either stan-
dard glucose control or intensive glucose control, defined as the use of gliclazide 
(modified release) plus other drugs as required to achieve a glycated hemoglobin 
value of 6.5% or less. Primary end points were composites of major macrovascular 
events (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal 
stroke) and major microvascular events (new or worsening nephropathy or retinopa-
thy), assessed both jointly and separately.
Results
After a median of 5 years of follow-up, the mean glycated hemoglobin level was 
lower in the intensive-control group (6.5%) than in the standard-control group (7.3%). 
Intensive control reduced the incidence of combined major macrovascular and micro-
vascular events (18.1%, vs. 20.0% with standard control; hazard ratio, 0.90; 95% 
confidence interval [CI], 0.82 to 0.98; P = 0.01), as well as that of major microvascular 
events (9.4% vs. 10.9%; hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P = 0.01), primarily 
because of a reduction in the incidence of nephropathy (4.1% vs. 5.2%; hazard ratio, 
0.79; 95% CI, 0.66 to 0.93; P = 0.006), with no significant effect on retinopathy 
(P = 0.50). There were no significant effects of the type of glucose control on major 
macrovascular events (hazard ratio with intensive control, 0.94; 95% CI, 0.84 to 1.06; 
P = 0.32), death from cardiovascular causes (hazard ratio with intensive control, 0.88; 
95% CI, 0.74 to 1.04; P = 0.12), or death from any cause (hazard ratio with intensive 
control, 0.93; 95% CI, 0.83 to 1.06; P = 0.28). Severe hypoglycemia, although uncom-
mon, was more common in the intensive-control group (2.7%, vs. 1.5% in the 
standard-control group; hazard ratio, 1.86; 95% CI, 1.42 to 2.40; P<0.001).
Conclusions
A strategy of intensive glucose control, involving gliclazide (modified release) and 
other drugs as required, that lowered the glycated hemoglobin value to 6.5% yielded 
a 10% relative reduction in the combined outcome of major macrovascular and 
microvascular events, primarily as a consequence of a 21% relative reduction in 
nephropathy. (ClinicalTrials.gov number, NCT00145925.)
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The prevalence of diabetes is increas-ing worldwide, and most people with dia-betes will die or be disabled as a conse-
quence of vascular complications.1,2 Prospective 
studies have shown continuous associations of 
blood glucose and glycated hemoglobin levels 
with the risks of major vascular events.3,4 How-
ever, previous randomized trials evaluating the 
effects of glycemic control in patients with dia-
betes have provided inconsistent evidence of ef-
fects on vascular disease.5-11 Nevertheless, current 
guidelines recommend a target glycated hemo-
globin level of 7.0% or less for most patients with 
diabetes.12-14
The Action in Diabetes and Vascular Disease: 
Preterax and Diamicron Modified Release Con-
trolled Evaluation (ADVANCE) trial was designed 
to assess the effects on major vascular outcomes 
of lowering the glycated hemoglobin value to a 
target of 6.5% or less in a broad cross-section of 
patients with type 2 diabetes. The part of the 
study that evaluated the lowering of blood pres-
sure with the use of perindopril and indapamide, 
completed in June 2007, showed a reduction in the 
risks of major vascular events and death, regard-
less of the initial blood pressure.15 Here we re-
port the main results from the comparison of the 
blood-glucose-lowering strategies, completed in 
January 2008, which evaluated an intensive glu-
cose-control strategy based on gliclazide (modi-
fied release) and other drugs as required to achieve 
the target glycated hemoglobin level.
Me thods
The ADVANCE trial is a factorial randomized, 
controlled trial conducted at 215 collaborating 
centers in 20 countries from Asia, Australasia, Eu-
rope, and North America (see the Supplementary 
Appendix, available with the full text of this ar-
ticle at www.nejm.org). Approval to conduct the 
trial was obtained from the ethics committee of 
each study center, and all participants provided 
written informed consent. Detailed study methods 
have been published previously.16
The ADVANCE trial was an investigator-initiat-
ed trial that was designed, conducted, analyzed, 
and had data interpreted independently of both 
sponsors. Study data were collected and retained 
by the investigators and were not made available 
to the study sponsors. The writing committee and 
the management committee, whose membership 
did not include any sponsor representatives, had 
final responsibility for the manuscript prepara-
tion and the decision to submit for publication. 
The first five authors vouch for the validity and 
completeness of the reported data.
Participants
Eligibility criteria, as detailed previously,16 were a 
diagnosis of type 2 diabetes mellitus at 30 years 
of age or older, an age of at least 55 years at the 
time of study entry, and a history of major macro-
vascular or microvascular disease or at least one 
other risk factor for vascular disease. There were no 
inclusion or exclusion criteria related to glycated 
hemoglobin. Exclusion criteria included a definite 
indication for, or contraindication to, any of the 
study treatments or a definite indication for long-
term insulin therapy at the time of study entry.
Study Treatment
Potentially eligible participants entered a 6-week 
run-in period, during which they continued their 
usual methods of glucose control and received a 
fixed combination of perindopril and indapamide. 
Those who tolerated and were compliant with the 
treatment during the run-in period were randomly 
assigned, according to a factorial design, to re-
ceive continued therapy with either perindopril 
and indapamide or matching placebo and to un-
dergo either a strategy of intensive blood glucose 
control (target glycated hemoglobin value, ≤6.5%) 
or a strategy of standard glucose control (with tar-
get glycated hemoglobin levels defined on the ba-
sis of local guidelines). Central, computer-based 
randomization was stratified according to several 
factors,16 including study center and presence or 
absence of a history of major vascular disease.
Patients who were randomly assigned to under-
go intensive glucose control were given gliclazide 
(modified release, 30 to 120 mg daily) and were 
required to discontinue any other sulfonylurea. 
Although the timing, selection, and doses of all 
other treatments were at the discretion of the 
treating physician, a treatment protocol was sug-
gested (see the Supplementary Appendix). On the 
basis of the glycated hemoglobin level at each 
visit, this protocol initially advised increasing 
the dose of gliclazide (modified release), with 
the sequential addition or increase in dose of 
metformin, thiazolidinediones, acarbose, or in-
sulin (advising the initial use of basal insulin, 
with the addition of short-acting insulin at meals 
for patients in whom the target glycated hemo-
globin level was not achieved, despite acceptable 
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fasting blood glucose levels). Patients in the 
standard-control group who were using glicla-
zide (modified release) when they entered the 
study were required to substitute this drug with 
another sulfonylurea, if continued therapy was 
required.
Follow-up Schedule
Patients in the intensive-control group were seen 
at week 2 after randomization; then at months 1, 
2, 3, 4, and 6; and every 3 months thereafter. 
These patients were also encouraged to attend 
other, unscheduled visits to improve the monitor-
ing and intensification of glucose control. Partici-
pants assigned to undergo standard control were 
seen at 3, 4, and 6 months after randomization 
and every 6 months thereafter. At study visits 
common to both groups, information was col-
lected on blood glucose, glycated hemoglobin, 
blood pressure, and lipids, as well as adherence 
to, and tolerability of, study treatments and occur-
rence of study outcomes. At the 2-year, 4-year, 
and final visits, the ratio of urinary albumin to 
creatinine was measured and a retinal examina-
tion, the Mini–Mental State Examination, and 
quality-of-life assessment were also performed. At 
study visits for patients in the intensive-control 
group only, the information collected was limited 
to blood glucose, glycated hemoglobin, and glu-
cose-lowering treatments.
Laboratory Measurements
All measurements were performed in local labora-
tories, and each glycated hemoglobin measure-
ment was standardized (see the Supplementary 
Appendix).17 Blood glucose measurements were 
performed on samples of venous or capillary 
blood, depending on local practice.
End Points
The primary study outcomes were a composite of 
macrovascular events and a composite of micro-
vascular events, considered both jointly and sepa-
rately. Macrovascular events were defined as death 
from cardiovascular causes, nonfatal myocardial 
infarction, or nonfatal stroke. Microvascular events 
were defined as new or worsening nephropathy 
(i.e., development of macroalbuminuria, defined as 
a urinary albumin:creatinine ratio of more than 
300 μg of albumin per milligram of creatinine 
[33.9 mg per millimole], or doubling of the serum 
creatinine level to at least 200 μmol per liter 
[2.26 mg per deciliter], the need for renal-replace-
ment therapy, or death due to renal disease) or reti-
nopathy (i.e., development of proliferative retinop-
athy, macular edema or diabetes-related blindness 
or the use of retinal photocoagulation therapy).
Prespecified secondary outcomes were death 
from any cause, death from cardiovascular caus-
es, major coronary events (death due to coronary 
heart disease [including sudden death] or non-
fatal myocardial infarction), total coronary events 
(major coronary events, silent myocardial infarc-
tion, coronary revascularization, or hospital ad-
mission for unstable angina), major cerebrovascu-
lar events (death due to cerebrovascular disease 
or nonfatal stroke), total cerebrovascular events 
(major cerebrovascular events, transient ischemic 
attack, or subarachnoid hemorrhage), heart fail-
ure (death due to heart failure, hospitalization for 
heart failure, or worsening New York Heart As-
sociation class), peripheral vascular events, all 
cardiovascular events, new or worsening nephrop-
athy, new or worsening retinopathy, development 
of microalbuminuria (urinary albumin:creatinine 
ratio, 30 to 300 μg per milligram [0.34 to 33.9 mg 
per millimole]), visual deterioration, new or wors-
ening neuropathy, decline in cognitive function 
(reduction in the Mini–Mental State Examination 
score by at least 3 points, as compared with the 
baseline score), dementia (satisfying the criteria 
in the Diagnostic and Statistical Manual of Mental Dis-
orders, 4th Edition), and hospitalization for 24 hours 
or more. Hypoglycemia was defined as a blood 
glucose level of less than 2.8 mmol per liter (50 mg 
per deciliter) or the presence of typical symptoms 
and signs of hypoglycemia without other apparent 
cause. Patients with transient dysfunction of the 
central nervous system who were unable to treat 
themselves (requiring help from another person) 
were considered to have severe hypoglycemia.
An independent End Point Adjudication Com-
mittee, unaware of the group assignments, re-
viewed source documentation for all suspected 
primary end points and deaths. An independent 
data and safety monitoring committee reviewed 
the unblinded data at regular intervals.
Statistical Analysis
The ADVANCE trial was originally designed to 
have a statistical power of 90% to detect a rela-
tive risk reduction of 16% or more for intensive 
control, as compared with standard control, for 
each of the primary outcomes, with the use of a 
two-tailed test with an alpha level of 5%. After a 
mean of approximately 3 years of follow-up, it be-
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came apparent that the event rates (in the two 
groups combined) were lower than expected. Thus, 
in a manner blinded to any results of the effects 
of intervention, two changes were made to the 
protocol to increase the power of the study: joint 
(as well as separate) analysis of the primary out-
comes was prespecified, and the period of treat-
ment and follow-up was extended by 12 months 
for the part of the study that evaluated the lower-
ing of blood pressure and by 18 months for the 
part that evaluated the control of blood glucose.
All analyses were conducted according to the 
intention-to-treat principle. Effects of treatment 
on study end points were estimated with the use 
of unadjusted Cox proportional-hazard models, 
involving survival time to the first relevant end 
point in any individual patient. Data for patients 
were censored at their date of death, date of last 
visit (for those still alive at the end of the follow-
up period), or date when last known to be alive 
(for those with unknown vital status). Differences 
in continuous variables between the two study 
groups during the follow-up period were estimat-
ed with the use of linear mixed models. The num-
bers needed to treat were calculated as recipro-
cals of the absolute differences in risk with their 
normally approximated 95% confidence inter-
vals.18 All P values were two-sided, and P values 
less than 0.05 were considered to indicate statis-
tical significance. No adjustment for multiple 
statistical testing was made.19
The homogeneity of treatment effects across 
subgroups (none of which were prespecified) was 
tested by adding interaction terms to the relevant 
Cox models. Interaction between the blood-pres-
sure intervention and the blood-glucose interven-
tion in the ADVANCE trial was assessed with the 
use of the database locked at the end of the period 
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Figure 1. Enrollment, Randomization, and Follow-up of Study Participants.
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Table 1. Characteristics of Participants at Baseline and at the End of the Follow-up Period.*
Characteristic Baseline End of Follow-up
Intensive Control 
(N = 5571)
Standard Control 
(N = 5569)
Intensive Control 
(N = 4828)
Standard Control 
(N = 4741)
Age — yr 66±6 66±6
Female sex — no. (%) 2376 (42.6) 2357 (42.3)
Age when diabetes first diagnosed — yr 58±9 58±9
Duration of diabetes — yr 7.9±6.3 8.0±6.4
Region — no. (%)
Australia and New Zealand 744 (13.4) 741 (13.3)
Asia 2069 (37.1) 2067 (37.1)
Europe 2538 (45.6) 2545 (45.7)
North America 220 (4.0) 216 (3.9)
Previous vascular disease
History of major macrovascular disease — no. (%) 1794 (32.2) 1796 (32.3)
Myocardial infarction 668 (12.0) 666 (12.0)
Stroke 515 (9.2) 508 (9.1)
Other 683 (12.3) 678 (12.2)
History of major microvascular disease — no. (%) 571 (10.3) 584 (10.5)
Macroalbuminuria† 189 (3.4) 215 (3.9)
Microvascular eye disease‡ 403 (7.2) 392 (7.0)
History of microalbuminuria — no. (%) 1434 (27.0) 1423 (26.7)
Blood-glucose control
Glycated hemoglobin, nonstandardized level — %
Mean ±SD 7.51±1.57 7.52±1.54 6.53±0.91 7.30±1.26
Median 7.2 7.2 6.4 7.0
Interquartile range 6.5–8.2 6.5–8.2 6.0–6.8 6.5–7.9
Glycated hemoglobin, standardized level — %
Mean ±SD 7.48±1.65 7.48±1.63 6.49±0.99 7.24±1.38
Median 7.2 7.2 6.3 7.0
Interquartile range 6.4–8.2 6.4–8.2 5.9–6.9 6.4–7.9
Fasting blood glucose — mmol/liter
Mean ±SD 8.51±2.78 8.48±2.76 6.56±1.88 7.75±2.34
Median 7.9 7.9 6.2 7.3
Interquartile range 6.6–9.7 6.6–9.7 5.4–7.3 6.2–8.7
Other major risk factors
Blood pressure — mm Hg
Systolic 145.0±21.7 145.0±21.4 135.5±17.6 137.9±18.4
Diastolic 80.8±11.0 80.5±10.8 73.5±9.8 74.3±9.9
Serum cholesterol — mmol/liter
Low-density lipoprotein 3.12±1.04 3.11±1.02 2.64±0.97 2.65±1.06
High-density lipoprotein 1.26±0.35 1.25±0.35 1.24±0.35 1.25±0.35
Serum triglycerides — mmol/liter
Median 1.60 1.64 1.45 1.59
Interquartile range 1.20–2.30 1.20–2.30 1.03–2.03 1.10–2.20
Serum triglycerides — μmol/liter 1.95±1.29 1.96±1.29 1.70±1.06 1.82±1.15
Serum creatinine — μmol/liter 86±24 87±27 94±37 93±41
Weight — kg 78.2±16.8 78.0±16.8 78.1±17.5 77.0±16.7
Body-mass index§ 28±5 28±5 28±5 28±5
Waist circumference — cm 99±13 98±13 99±14 98±13
Current smoking — no. (%) 793 (14.2) 757 (13.6) 385 (8.3) 350 (7.8)
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of follow-up for the blood-pressure-lowering part 
of the study (average duration of follow-up, 4.3 
years). All analyses were performed with the use 
of SAS software, version 9.1 (SAS Institute).
R esult s
Enrollment and Baseline Characteristics  
of Participants
Between June 2001 and March 2003, a total of 
12,877 potentially eligible participants were reg-
istered, 1737 (13.5%) were withdrawn during the 
run-in period, and 11,140 (86.5%) underwent ran-
domization (Fig. 1). The median duration of fol-
low-up was 5.0 years. The two groups had similar 
characteristics at baseline (Table 1, and Table 1 in 
the Supplementary Appendix). The mean baseline 
glycated hemoglobin was 7.5%, and the mean 
fasting blood glucose level was 8.5 mmol per liter 
(153 mg per deciliter). At baseline, 91% of patients 
were receiving oral hypoglycemic agents.
Effects on Glycated Hemoglobin  
and Fasting Blood Glucose
At the end of the follow-up period, the mean glycat-
ed hemoglobin values were 6.5% in the intensive-
control group and 7.3% in the standard-control 
group. During the follow-up period, the time-
weighted average glycated hemoglobin level was 
reduced by 0.67 percentage point and the fast-
ing blood glucose level by 1.2 mmol per liter 
(21.9 mg per deciliter) among patients undergo-
ing intensive control as compared with those un-
dergoing standard control (Fig. 2).
Effects on Other Risk Factors
Table 1 describes the levels of other risk factors 
among study participants. At the end of the follow-
up period, the mean systolic blood pressure was 
lower in the intensive-control group than in the 
standard-control group (135.5 vs. 137.9 mm Hg; 
average difference, 1.6 mm Hg; P<0.001) (Table 1). 
This difference was apparent at the first common 
Table 1. (Continued.)
Characteristic Baseline End of Follow-up
Intensive Control 
(N = 5571)
Standard Control 
(N = 5569)
Intensive Control 
(N = 4828)
Standard Control 
(N = 4741)
Glucose-lowering drug
Gliclazide (modified release) — no. (%)¶ 422 (7.6) 443 (8.0) 4209 (90.5) 80 (1.6)
Other sulfonylurea — no. (%) 3578 (64.2) 3513 (63.1) 89 (1.9) 2606 (57.1)
Metformin — no. (%) 3397 (61.0) 3355 (60.2) 3455 (73.8) 3057 (67.0)
Thiazolidinedione — no. (%) 201 (3.6) 206 (3.7) 788 (16.8) 495 (10.9)
Acarbose — no. (%) 512 (9.2) 448 (8.0) 891 (19.1) 576 (12.6)
Glinide — no. (%) 103 (1.8) 84 (1.5) 58 (1.2) 127 (2.8)
Any oral hypoglycemic drug — no. (%) 5084 (91.3) 5045 (90.6) 4525 (93.7) 4001 (84.4)
Insulin — no. (%) 82 (1.5) 77 (1.4) 1953 (40.5) 1142 (24.1)
None — no. (%) 487 (8.7) 524 (9.4) 42 (1.5) 220 (6.4)
Other drugs
Aspirin — no. (%) 2460 (44.2) 2435 (43.7) 2665 (57.0) 2503 (54.9)
Other antiplatelet agent — no. (%) 271 (4.9) 235 (4.2) 333 (7.1) 284 (6.2)
Statins — no. (%) 1554 (27.9) 1592 (28.6) 2131 (45.6) 2174 (47.7)
Other lipid-modifying drug — no. (%) 501 (9.0) 435 (7.8) 326 (7.0) 317 (7.0)
Any blood-pressure–lowering drug — no. (%) 4183 (75.1) 4182 (75.1) 4291 (88.9) 4190 (88.4)
* Plus–minus values are means ±SD. Baseline characteristics were recorded at the first (registration) visit, before the start of the active run-in 
period. Data are based on the number of patients who attended each visit and who had data for the characteristic. Glycated hemoglobin val-
ues were standardized as described in the Supplementary Appendix. To convert the values for blood glucose to milligrams per deciliter, di-
vide by 0.05551. To convert the values for cholesterol to milligrams per deciliter, divide by 0.02586. To convert the values for triglycerides to 
milligrams per deciliter, divide by 0.01129. To convert the values for creatinine to milligrams per deciliter, divide by 88.4.
† Macroalbuminuria was defined as a urinary albumin:creatinine ratio of more than 300 μg of albumin per milligram of creatinine (33.9 mg 
per millimole).
‡ Microvascular eye disease was defined as proliferative diabetic retinopathy, retinal photocoagulation therapy, macular edema, or blindness 
thought to be caused by diabetes in at least one eye.
§ The body-mass index is the weight in kilograms divided by the square of the height in meters.
¶ The use of gliclazide (modified release) at baseline in the intensive-control group is reported for the first (registration) visit; at the random-
ization visit, 99% of patients in this group were given the drug.
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post-randomization visit (at 3 months) and all sub-
sequent common visits (Fig. 1 in the Supplemen-
tary Appendix). The mean body weight during the 
follow-up period was 0.7 kg greater in the inten-
sive-control group than in the standard-control 
group (P<0.001).
Use of Glucose-Lowering Therapy  
and Other Treatments
On average, each patient in the intensive-control 
group attended 31 study visits, as compared with 
11 for each patient in the standard-control group, 
over the course of the trial period. During the 
follow-up period, the use of most classes of oral 
hypoglycemic drug and of insulin had increased 
to a greater degree in the intensive-control group 
than in the standard-control group (Table 1, and 
Table 1 in the Supplementary Appendix). In the 
intensive-control group, 90% of patients attend-
ing the final visit were still receiving gliclazide 
(modified release), 70.4% of whom were taking 
120 mg of the drug daily. Insulin was prescribed 
for 40.5% and 24.1% of patients in the intensive-
control group and the standard-control group, 
respectively, by the end of the follow-up period. 
At the final visit, 16.8% of patients undergoing 
intensive glucose control and 10.9% of those un-
dergoing standard glucose control were receiving 
thiazolidinediones. The use of blood-pressure–
lowering, lipid-modifying, and antiplatelet treat-
ments was similar between the two groups dur-
ing the follow-up period.
Effects on Primary Outcomes
A total of 2125 participants had a major macro-
vascular or microvascular event: 18.1% in the in-
tensive-control group and 20.0% in the standard-
control group (hazard ratio, 0.90; 95% confidence 
interval (CI), 0.82 to 0.98; P = 0.01) (Fig. 3). Thus, 
it was estimated that such an event would be 
averted during a 5-year period in 1 of every 52 
participants (95% CI, 30 to 213) undergoing in-
tensive control. As compared with standard con-
trol, intensive control resulted in a significant re-
duction in the incidence of major microvascular 
events (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; 
P = 0.01) but not in the incidence of major macro-
vascular events (hazard ratio, 0.94; 95% CI, 0.84 
to 1.06; P = 0.32). There was no evidence of an 
interaction between the blood-pressure interven-
tion and the blood-glucose intervention in the 
ADVANCE trial for the primary outcomes (P>0.50 
for all comparisons).
Effects on Death and Other Secondary 
Outcomes
A total of 1031 participants died: 8.9% in the in-
tensive-control group and 9.6% in the standard-
control group (hazard ratio, 0.93; 95% CI, 0.83 to 
1.06; P = 0.28) (Fig. 3). As compared with stan-
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Figure 2. Glucose Control at Baseline and during Follow-up, According to 
Glucose-Control Strategy.
Data are shown for mean glycated hemoglobin (Panel A) and mean fasting 
blood glucose (Panel B). The average difference between the intensive-con-
trol group and the standard-control group for the follow-up period was 0.67 
percentage point (95% confidence interval [CI], 0.64 to 0.70) for glycated 
hemoglobin and 1.22 mmol per liter (21.9 mg per deciliter) (95% CI, 1.15 to 
1.28 [20.8 to 23.0]) for fasting blood glucose.
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dard control, intensive control was associated with 
a significant reduction in renal events, including 
new or worsening nephropathy (hazard ratio, 0.79; 
95% CI, 0.66 to 0.93; P = 0.006) and new-onset 
microalbuminuria (hazard ratio, 0.91; 95% CI, 
0.85 to 0.98; P = 0.02) (Fig. 4). The component of 
new or worsening nephropathy most clearly re-
duced through intensive glucose control was the 
development of macroalbuminuria (2.9%, vs. 
4.1% with standard control; hazard ratio, 0.70; 
95% CI, 0.57 to 0.85; P<0.001), with a trend to-
ward a reduction in the need for renal-replace-
ment therapy or death from renal causes (0.4% 
vs. 0.6%; hazard ratio, 0.64; 95% CI, 0.38 to 1.08; 
P = 0.09) but no effect on the doubling of serum 
creatinine level (1.2% vs. 1.1%; hazard ratio, 1.15; 
95% CI, 0.82 to 1.63; P = 0.42). More patients 
undergoing intensive control were hospitalized 
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Figure 3. Cumulative Incidences of Events, According to Glucose-Control Strategy.
The hazard ratios for intensive glucose control as compared with standard glucose control were as follows: for combined major macro-
vascular or microvascular events, 0.90 (95% confidence interval [CI], 0.82 to 0.98) (Panel A); for major macrovascular events, 0.94 (95% CI, 
0.84 to 1.06) (Panel B); for major microvascular events, 0.86 (95% CI, 0.77 to 0.97) (Panel C); and for death from any cause, 0.93 (95% CI, 
0.83 to 1.06) (Panel D). The vertical dashed lines indicate the 24-month and 48-month study visits, at which additional data on microvascu-
lar events were collected, specifically the ratio of urinary albumin to creatinine and results of a retinal examination. For events relating to 
these data, the event time was recorded as the date of the visit. The curves were truncated at month 66, by which time 99% of the events 
had occurred. The effects of treatment (hazard ratios and P values) were estimated from unadjusted Cox proportional-hazard models 
that used all the available data.
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for any cause (44.9%, vs. 42.8% of those in the 
standard-control group; hazard ratio, 1.07; 95% 
CI, 1.01 to 1.13; P = 0.03), with some of the excess 
of hospitalizations due to severe hypoglycemia 
(1.1% vs. 0.7%; odds ratio, 1.52; 95% CI, 1.01 to 
2.28; P = 0.04). There were no significant differ-
ences between the two groups for any of the 
other prespecified secondary outcomes (Fig. 4).
Effects on Hypoglycemia
Severe hypoglycemia occurred more frequently in 
the intensive-control group than in the standard-
control group: 150 patients (2.7%) undergoing 
intensive control had at least one severe hypogly-
cemic episode, as compared with 81 patients 
(1.5%) undergoing standard control (hazard ratio, 
1.86; 95% CI, 1.42 to 2.40; P<0.001). These in-
cluded one fatal episode in the standard-control 
group and one episode resulting in permanent 
disability in each group. On average, the rate of 
severe hypoglycemic events was 0.7 event per 100 
patients per year in the intensive-control group 
and 0.4 event per 100 patients per year in the 
standard-control group. Minor hypoglycemia also 
occurred more frequently in patients undergoing 
intensive control (120 events per 100 patients per 
year, vs. 90 with standard control). Approximate-
ly 47% of patients in the intensive-control group 
and 62% of those in the standard-control group 
remained free of any hypoglycemic event during 
the follow-up period.
Effects in Subgroups of Patients
The effects of intensive control on major vascular 
events were consistent across participant sub-
groups, as defined by a range of baseline charac-
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Figure 4. Relative Effects of Glucose-Control Strategy on All Prespecified Primary and Secondary Outcomes.
The diamonds incorporate the point estimates, represented by th  vertical dashed lines, and the 95% confidence intervals of the overall 
 effects within categories; for subcategories, black squares represent point estimates (with the area of the square proportional to the 
number of events), and horizontal lines represent 95% confidence intervals. The hazard ratios and relative risk reductions are given for 
intensive glucose control as compared with standard glucose control.
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teristics (P for heterogeneity, ≥0.10 for all com-
parisons) (Fig. 5).
Discussion
In the ADVANCE trial, an intensive glucose-con-
trol strategy involving gliclazide (modified re-
lease), and other drugs as required, lowered the 
average glycated hemoglobin value to 6.5% in a 
broad range of patients with type 2 diabetes and 
reduced the incidence of the combined primary 
outcome of major macrovascular or microvascu-
lar events. The main contributor to the 10% rela-
tive reduction in the primary outcome found with 
intensive control as compared with standard con-
trol was a 21% relative reduction in the risk of 
new or worsening nephropathy. There was no 
evidence of a reduction in macrovascular events. 
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Figure 5. Effects of Glucose-Control Strategy on Combined Major Macrovascular and Microvascular Events, According to Baseline 
 Characteristics.
The diamond incorporates the point estimate, represented by the vertical dashed line, and the 95% confidence interval of the overall 
 effect. The hazard ratios and relative risk reductions are given for intensive glucose control as compared with standard glucose control. 
The P value for heterogeneity was ≥0.10 for all comparisons. Data were not available for some patients in some subgroups. The body-
mass index is the weight in kilograms divided by the square of the height in meters.
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Intensive glucose control was associated with an 
increased risk of severe hypoglycemia and an in-
creased rate of hospitalization, as compared with 
standard control. There was no evidence that the 
effects of intensive glucose control were depen-
dent on the baseline glycated hemoglobin or 
blood glucose level, age, sex, or presence or ab-
sence of a history of vascular disease.
There were no significant differences be-
tween the two study groups in the rate of death 
from any cause or death from cardiovascular 
causes. These findings contrast with the report-
ed excess mortality that led to premature termi-
nation of the intensive glucose-control strategy 
in another large, randomized trial involving 
patients with type 2 diabetes (Action to Control 
Cardiovascular Risk in Diabetes [ACCORD]; 
ClinicalTrials.gov number, NCT00000620), in 
which similar levels of glucose control were 
achieved with the intensive-control strategy.20,21 
Mechanisms speculated to underlie the excess 
mortality found with intensive glucose control 
in the ACCORD trial include the initial level of 
glycated hemoglobin, the degree and pace of 
glucose lowering, and the treatments used to 
achieve such lowering.20,22 In the ADVANCE tri-
al, no subgroup of participants was identified to 
have evidence of an adverse effect of intensive 
glucose lowering on major vascular outcomes, 
including the subgroup with an initial median 
glycated hemoglobin value similar to that in the 
ACCORD study population.21
Intensive glucose control in the ADVANCE 
trial resulted in a reduction by one fifth in the 
development of new or worsening nephropathy 
and a more modest, though significant, reduc-
tion in that of new-onset microalbuminuria. In 
the U.K. Prospective Diabetes Study (UKPDS), 
the largest previously reported randomized trial 
of glycemic control in patients with type 2 dia-
betes, tighter glucose control did not reduce the 
incidence of major renal outcomes, although 
there was some evidence of a reduction in the 
development of microalbuminuria and overt pro-
teinuria with a prolonged follow-up period.6 The 
clear reduction in nephropathy demonstrated in 
the ADVANCE trial is important, because index-
es of renal impairment are strongly associated 
with the future risk of major vascular events, 
end-stage renal disease, and death in patients 
with diabetes.23,24
There is no evidence that intensive glucose 
control in the ADVANCE trial led to reduced new 
or worsening retinopathy, including retinal pho-
tocoagulation. The lower rate of retinal photoco-
agulation in the ADVANCE trial than in previous 
studies of diabetes7,25 was also reported in an-
other recent trial.26 This low event rate limited 
the power of the study to detect any moderate 
effects of the intervention on microvascular eye 
disease. However, more evidence about the reti-
novascular effects of intensive glucose control 
will be provided by the ADVANCE retinal imag-
ing substudy.27
The ADVANCE trial did not show a signifi-
cant effect of intensive glucose control on the 
risk of major macrovascular events. Although 
the results may indicate that lowering blood 
glucose levels to an average glycated hemoglobin 
level of 6.5% with the treatments used does not 
reduce the risk of macrovascular events, the re-
sults do not preclude a benefit of the size pre-
dicted by the achieved difference between the 
intensive-control group and the standard-control 
group in glycated hemoglobin levels. From ob-
servational data describing the association be-
tween glycated hemoglobin and cardiovascular 
events and a meta-analysis of previous random-
ized trials of glycemic control,4,10 a 0.7% reduc-
tion in the glycated hemoglobin value might be 
expected to produce a reduction in the rate of 
macrovascular events by approximately one 
sixth. The confidence intervals for the estimate 
of the effect of treatment on macrovascular 
events in the ADVANCE trial are consistent with 
such a reduction, but the ADVANCE trial did not 
have adequate statistical power to detect such an 
effect reliably. The annual rate of macrovascular 
events (2.2%) was lower than the anticipated 
rate of 3.0% based on previous studies of pa-
tients with type 2 diabetes,7,25 possibly as a con-
sequence of the greater use of statins, blood-
pressure–lowering drugs, and antiplatelet agents. 
Future combined analyses of the ADVANCE trial, 
the ACCORD trial, and other studies should 
provide further insight into the effects of inten-
sive glucose control on macrovascular events.21,28
In the part of the ADVANCE trial evaluating 
the lowering of blood pressure,15 a reduction of 
5.6 mm Hg in the systolic blood pressure among 
patients randomly assigned to receive perindo-
pril and indapamide, as compared with those 
assigned to receive placebo, resulted in a relative 
risk reduction of 9% for the primary combined 
outcome. Thus, the expected relative risk reduc-
tion associated with a 1.6 mm Hg reduction in 
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systolic blood pressure would be less than 3%. 
This suggests that the lower blood pressure 
among patients undergoing intensive glucose con-
trol probably explains some, but no more than 
one quarter to one third, of the 10% reduction 
seen with intensive glucose control as compared 
with standard control. The explanation for the 
reduction in blood pressure in the intensive-con-
trol group is unclear. The difference in blood 
pressure so soon after randomization may indi-
cate an early effect of the study treatment regi-
men.29-31 However, it is also possible that the dif-
ference reflects nonspecific effects associated with 
more frequent contact with health care providers.
As expected, there was a significantly higher 
incidence of hypoglycemia in the intensive-con-
trol group (three additional severe events for 
every 1000 patients treated for 1 year), although 
the overall risk of this complication was low. 
Almost half of all patients undergoing intensive 
control remained free from any hypoglycemia 
(severe or minor) during the follow-up period. 
The proportion of patients with at least one se-
vere hypoglycemic episode each year was about 
one quarter that observed in the UKPDS,6 de-
spite the lower glycated hemoglobin levels 
among the ADVANCE participants.
In the ADVANCE trial, an intensive glucose-
control strategy involving gliclazide (modified re-
lease) and other glucose-lowering drugs as re-
quired reduced the glycated hemoglobin level to 
an average of 6.5%. There was no evidence that 
this treatment strategy increased mortality.20,21 
Intensive glucose control significantly reduced 
the primary composite outcome of major macro-
vascular or microvascular events, mainly as a 
consequence of a reduction in nephropathy. 
There was no separately significant reduction in 
major macrovascular events, although a modest 
benefit could not be ruled out. However, it is 
clear that the prevention of macrovascular com-
plications of diabetes requires a multifactorial 
approach32 addressing all major modifiable risk 
factors, including blood pressure33 and blood lip-
ids.34 The main benefit conferred by the ADVANCE 
treatment regimen was a one-fifth reduction in 
renal complications, indicating that intensive 
control of glucose has an important role in the 
prevention of microvascular complications of 
type 2 diabetes.
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